Vertex already has FDA approval for NaV1.8 inhibitor Journavx (suzetrigine) in acute pain, with late-stage trials on the go ...

The deal with Arrowhead's Visirna Therapeutics subsidiary – which also includes $265 million in milestones tied to potential ...

The importance of China as a growth market for pharma multinationals is underlined by the news that Sanofi has paid $130 million upfront for Chinese rights to an Arrowhead Pharma drug under review for ...

Earlier this year, Bayer formed a new business unit that promised to shake up the consumer health category with a new personalised approach driven by digital technologies. Now, it has taken the ...

pharmaphorum editor in chief Jonah Comstock talks to Philip Gomez, CEO of Siga Technologies, about how his company’s antiviral drug can play a crucial role in addressing monkeypox cases.

An antisense drug in development at GSK has shown further activity against hepatitis B virus (HBV) in a mid-stage trial, setting up a phase 3 assessment next year to see if it could offer a ...

Merck gets another quick return on its $3.9bn SpringWorks takeover with EU approval of Ezmekly for tumours caused by neurofibromatosis type 1.

Pharmaceutical companies are increasingly focusing on radiopharmaceuticals due to their potential in oncology and therapeutic applications. Learn more about why the industry is excited about ...

Endo Pharmaceuticals has removed its Opana ER opioid painkiller from the US market at the request of the FDA.

Explore the latest pharmaceutical trends and predictions for 2025 from an incoming CEO's perspective. Stay ahead of the curve and prepare your organisation for the future.

The UK has been a global leader in introducing cell and gene therapies that can potentially transform the lives of patients with debilitating diseases – but there are still many barriers to ...

The recent move to introduce an “Amazon-style” prescription tracking in the NHS App is a crucial first step. People want ...